Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Phase 4 Completed 313 enrolled Allergan

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.

Timeline

Start: 2016-11-29
Primary completion: 2019-03-29
Completion: 2019-03-29

Publications

Talan DA, Mower WR, Lovecchio FA, Rothman RE, Steele MT, Keyloun K, Gillard P, Copp R, Moran GJ. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Acad Emerg Med. 2021 Oct;28(10):1108-1117. doi: 10.1111/acem.14258. Epub 2021 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dalbavancin	Other / unclassified	1500 mg	Intravenous

Indications

No indication recorded.